DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response

Molecular and Cellular Biology

Volumn 26, Issue 5, 2006, Pages 1598-1609

  Freiberg, Rachel A ^a   Hammond, Ester M ^a   Dorie, Mary Jo ^a   Welford, Scott M ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; HYPOXIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REOXYGENATION; SOLID TUMOR; TUMOR VASCULARIZATION;

ACETYLCYSTEINE; APOPTOSIS; ATAXIA TELANGIECTASIA; CARCINOMA; CDC25 PHOSPHATASE; CELL HYPOXIA; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA DAMAGE; FREE RADICAL SCAVENGERS; G2 PHASE; HUMANS; OXYGEN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; THREONINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ATAXIA TELANGIECTASIA;

EID: 33644505462     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.26.5.1598-1609.2006     Document Type: Article

References (74)

1. Abraham, R. T. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177-2196.
2. Adamson, A. W., D. I. Beardsley, W. J. Kim, Y. Gao, R. Baskaran, and K. D. Brown. 2005. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol. Biol. Cell 16:1513-1526.
3. Ahn, J. Y., J. K. Schwarz, H. Piwnica-Worms, and C. E. Canman. 2000. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60:5934-5936.
4. Bakkenist, C. J., and M. B. Kastan. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
5. Bartek, J., J. Falck, and J. Lukas. 2001. CHK2 kinase-a busy messenger. Nat Rev. Mol. Cell Biol. 2:877-886.
6. Bartkova, J., P. Guldberg, K. Gronbaek, K. Koed, H. Primdahl, K. Moller, J. Lukas, T. F. Orntoft, and J. Bartek. 2004. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23:8545-8551.
7. Bartkova, J., Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas, and J. Bartek. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
8. Barzilai, A., and K. Yamamoto. 2004. DNA damage responses to oxidative stress. DNA Repair (Amsterdam) 3:1109-1115.
9. Bertoni, F., A. M. Codegoni, D. Furlan, M. G. Tibiletti, C. Capella, and M. Broggini. 1999. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 26:176-180.
10. Boyer, J. C., A. Umar, J. I. Risinger, J. R. Lipford, M. Kane, S. Yin, J. C. Barrett, R. D. Kolodner, and T. A. Kunkel. 1995. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 55:6063-6070.
11. Brown, J. M. 2002. Tumor microenvironment and the response to anticancer therapy. Cancer Biol. Ther. 1:453-458.
12. Canman, C. E., D. S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.
13. Carethers, J. M., D. P. Chauhan, D. Fink, S. Nebel, R. S. Bresalier, S. B. Howell, and C. R. Boland. 1999. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131.
14. Chien, C. T., P. H. Lee, C. F. Chen, M. C. Ma, M. K. Lai, and S. M. Hsu. 2001. De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. J. Am. Soc. Nephrol. 12:973-982.
15. Cliby, W. A., C. J. Roberts, K. A. Cimprich, C. M. Stringer, J. R. Lamb, S. L. Schreiber, and S. H. Friend. 1998. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17:159-169.
16. Deep, G., R. P. Singh, C. Agarwal, D. J. Kroll, and R. Agarwal. 3 October 2005, posting date. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene [Online.] doi:10.1038/sj.onc.
17. Drumnumd, J. T., A. Anthoney, R. Brown, and P. Modrich. 1996. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271:19645-19648.
18. Fleisher, A. S., M. Esteller, G. Tamura, A. Rashid, O. C. Stine, J. Yin, T. T. Zou, J. M. Abraham, D. Kong, S. Nishizuka, S. P. James, K. T. Wilson, J. G. Herman, and S. J. Meltzer. 2001. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20:329-335.
19. Gibson, S. L., R. S. Bindra, and P. M. Glazer. 2005. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res. 65:10734-10741.
20. Goodarzi, A. A., J. C. Jonnalagadda, P. Douglas, D. Young, R. Ye, G. B. Moorhead, S. P. Lees-Miller, and K. K. Khanna. 2004. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 23:4451-4461.
21. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14:6264-6277.
22. Kip1 regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell. Biol. 21:1196-1206.
23. Hammond, E. M., N. C. Denko, M. J. Dorie, R. T. Abraham, and A. J. Giaccia. 2002. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22:1834-1843.
24. Hammond, E. M., M. J. Dorie, and A. J. Giaccia. 2003. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278:12207-12213.
25. Hammond, E. M., and A. J. Giaccia. 2004. The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amsterdam) 3:1117-1122.
26. Hammond, E. M., S. L. Green, and A. J. Giaccia. 2003. Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat. Res. 532:205-213.
27. Reference deleted.
28. Helt, C. E., W. A. Cliby, P. C. Keng, R. A. Bambara, and M. A. O'Reilly. 2005. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 280:1186-1192.
29. Hirao, A., A. Cheung, G. Duncan, P. M. Girard, A. J. Elia, A. Wakeham, H. Okada, T. Sarkissian, J. A. Wong, T. Sakai, E. De Stanchina, R. G. Bristow, T. Suda, S. W. Lowe, P. A. Jeggo, S. J. Elledge, and T. W. Mak. 2002. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 22:6521-6532.
30. Hirao, A., Y. Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D. Liu, S. J. Elledge, and T. W. Mak. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-1827.
31. Hockel, M., C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann, M. Mitze, P. G. Knapstein, and P. Vaupel. 1993. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50.
32. Hockel, M., K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509-4515.
33. Hockel, M., K. Schlenger, S. Hockel, and P. Vaupel. 1999. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59:4525-4528.
34. Hoffmann, I., P. R. Clarke, M. J. Marcote, E. Karsenti, and G. Draetta. 1993. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 12:53-63.
35. Izumi, T., and J. L. Maller. 1993. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Biol. Cell 4:1337-1350.
36. Jallepalli, P. V., C. Lengauer, B. Vogelstein, and F. Bunz. 2003. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J. Biol. Chem. 278:20475-20479.
37. Jinno, S., K. Suto, A. Nagata, M. Igarashi, Y. Kanaoka, H. Nojima, and H. Okayama. 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-1556.
38. Krtolica, A., and J. W. Ludlow. 1996. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res. 56:1168-1173.
39. Leach, F. S., N. C. Nicolaides, N. Papadopoulos, B. Liu, J. Jen, R. Parsons, P. Peltomaki, P. Sistonen, L. A. Aaltonen, M. Nystrom-Lahti, et al. 1993. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225.
40. Lee, J. S., K. M. Collins, A. L. Brown, C. H. Lee, and J. H. Chung. 2000. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404:201-204.
41. Li, C., M. M. Wright, and R. M. Jackson. 2002. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp. Lung Res. 28:373-389.
42. Liu, Q., S. Guntuku, X. S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, L. A. Donehower, and S. J. Elledge. 2000. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14:1448-1459.
43. Mailand, N, J. Falck, C. Lukas, R. G. Syljuasen, M. Welcker, J. Bartek, and J. Lukas. 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425-1429.
44. Mailand, N., A. V. Podtelejnikov, A. Groth, M. Mann, J. Bartek, and J. Lukas. 2002. Regulation of G(2)/M events by Cdc25A through phosphorylation- dependent modulation of its stability. EMBO J. 21:5911-5920.
45. Matsuoka, S., M. Huang, and S. J. Elledge. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897.
46. Matsuoka, S., T. Nakagawa, A. Masuda, N. Haruki, S. J. Elledge, and T. Takahashi. 2001. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res. 61:5362-5365.
47. Matsuoka, S., G. Rotman, A. Ogawa, Y. Shiloh, K. Tamai, and S. J. Elledge. 2000. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA 97:10389-10394.
48. Melchionna, R., X. B. Chen, A. Blasina, and C. H. McGowan. 2000. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat. Cell Biol. 2:762-765.
49. Menoyo, A., H. Alazzouzi, E. Espin, M. Armengol, H. Yamamoto, and S. Schwartz, Jr. 2001. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 61:7727-7730.
50. Nurse, P. 1990. Universal control mechanism regulating onset of M-phase. Nature 344:503-508.
51. Olive, P. L., J. P. Banath, and R. E. Durand. 1990. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res. 122:86-94.
52. Peng, C. Y., P. R. Graves, R. S. Thoma, Z. Wu, A. S. Shaw, and H. Piwnica-Worms. 1997. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505.
53. Saito, A., C. M. Maier, P. Narasimhan, T. Nishi, Y. S. Song, F. Yu, J. Liu, Y. S. Lee, C. Nito, H. Kamada, R. L. Dodd, L. B. Hsieh, B. Hassid, E. E. Kim, M. Gonzalez, and P. H. Chan. 2005. Oxidative stress and neuronal death/survival signaling in cerebral ischemia. Mol. Neurobiol. 31:105-116.
54. Seim, J., P. Graff, O. Amellem, K. S. Landsverk, T. Stokke, and E. O. Pettersen. 2003. Hypoxia-induced irreversible S-phase arrest involves down-regulation of cyclin A. Cell Prolif. 36:321-332.
55. Sexl, V., J. A. Diehl, C. J. Sherr, R. Ashmun, D. Beach, and M. F. Roussel. 1999. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene 18:573-582.
56. Shah-Yukich, A. A., and A. C. Nelson. 1988. Characterization of solid tumor microvasculature: a three-dimensional analysis using the polymer casting technique. Lab Investig. 58:236-244.
57. Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
58. Staalesen, V., J. Falck, S. Geisler, J. Bartkova, A. L. Borresen-Dale, J. Lukas, J. R. Lillehaug, J. Bartek, and P. E. Lonning. 2004. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23:8535-8544.
59. Sugawara, T., M. Fujimura, N. Noshita, G. W. Kim, A. Saito, T. Hayashi, P. Narasimhan, C. M. Maier, and P. H. Chan. 2004. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 1:17-25.
60. Takahashi, T., Z. Min, I. Uchida, M. Arita, Y. Watanabe, M. Koi, and H. Hemmi. 2005. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett. 220:85-93.
61. Takai, H., K. Naka, Y. Okada, M. Watanabe, N. Harada, S. Saito, C. W. Anderson, E. Appella, M. Nakanishi, H. Suzuki, K. Nagashima, H. Sawa, K. Ikeda, and N. Motoyama. 2002. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21:5195-5205.
62. Therade-Matharan, S., E. Laemmel, J. Duranteau, and E. Vicaut. 2004. Reoxygenation after hypoxia and glucose depletion causes reactive oxygen species production by mitochondria in HUVEC. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287:R1037-R1043.
63. Thomlinson, R. H., and L. H. Gray. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9:539-549.
64. Tomida, A., and T. Tsuruo. 1999. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 14:169-177.
65. Vassileva, V., A. Millar, L. Briollais, W. Chapman, and B. Bapat. 2002. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 62:4095-4099.
66. Vaupel, P., and M. Hockel. 2000. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol. 17:869-879.
67. Xiao, Z., Z. Chen, A. H. Gunasekera, T. J. Sowin, S. H. Rosenberg, S. Fesik, and H. Zhang. 2003. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 278:21767-21773.
68. Xiao, Z., J. Xue, T. J. Sowin, S. H. Rosenberg, and H. Zhang. 2005. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24:1403-1411.
69. Yang, W., and E. R. Block. 1995. Effect of hypoxia and reoxygenation on the formation and release of reactive oxygen species by porcine pulmonary artery endothelial cells. J. Cell. Physiol. 164:414-423.
70. Yu, Q., J. H. Rose, H. Zhang, and Y. Pommier. 2001. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505:7-12.
71. Zeman, E. M., D. P. Calkins, J. M. Cline, D. E. Thrall, and J. A. Raleigh. 1993. The relationship between proliferative and oxygenation status in spontaneous canine tumors. Int. J. Radiat. Oncol. Biol. Phys. 27:891-898.
72. Zhang, J., H. Willers, Z. Feng, J. C. Ghosh, S. Kim, D. T. Weaver, J. H. Chung, S. N. Powell, and F. Xia. 2004. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 24:708-718.
73. Ziv, Y., A. Bar-Shira, I. Pecker, P. Russell, T. J. Jorgensen, I. Tsartati, and Y. Shiloh. 1997. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 15:159-167.
74. Zulueta, J. J., R. Sawhney, F. S. Yu, C. C. Cote, and P. M. Hassoun. 1997. Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation. Am. J. Physiol. 272:L897-902.